RxDoctor Payments Data

Alexander Fishberg, MD

Family Medicine · Orlando, FLNPI 1225038391

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 45 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$301
  • Lilly USA, LLC$228
  • Johnson & Johnson$133
  • Novo Nordisk$114
  • Phathom Pharmaceuticals, Inc.$96
  • Vivus LLC$44
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,541
Medicare patients
78
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$59,419
EliquisApixaban67$52,627
OzempicSemaglutide36$34,305
RybelsusSemaglutide12$23,931
JardianceEmpagliflozin16$7,163
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,011
Atorvastatin Calcium245$2,655
Gabapentin98$1,963
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,709
Potassium Chloride34$1,578
Wixela InhubFluticasone Propion/Salmeterol12$1,550
Albuterol Sulfate HfaAlbuterol Sulfate54$1,529
Tamsulosin Hcl75$1,300
Amlodipine Besylate161$1,077
Levothyroxine Sodium83$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Olanzapine$228$59,84960 claims
Novo NordiskOzempic, Rybelsus$114$58,23748 claims
GSKAnoro Ellipta$15$5,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →